Isoindolinone and SGI-110 Combination for Selective p53 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those involving MDM2-p53 interaction and DNA methylation, face challenges in selectively activating p53-mediated cell death in tumors while minimizing effects on normal cells, and existing hypomethylating agents have limitations in boosting immune recognition of tumour-associated antigens.
Innovation Solution
Combining isoindolin-1-one derivatives that inhibit or modulate the MDM2-p53 interaction with a dinucleotide compound like SGI-110, a hypomethylating agent, to target abnormal cell growth and enhance immune recognition of cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MDM2-p53 interaction inhibitors are used to activate p53-mediated cell death, then tumor cell killing is improved, but selective activation in tumors while minimizing effects on normal cells remains challenging
Solution Approach 1:
The patent combines two mechanisms of action: MDM2-p53 interaction inhibition (via isoindolin-1-one derivatives) and DNA hypomethylation (via SGI-110). This combination synergistically enhances p53 activation and tumor cell killing while maintaining selectivity, as the dual mechanism targets multiple pathways involved in cancer progression simultaneously, improving the therapeutic index compared to single agents.
Solution Approach 2:
The combination therapy represents a composite treatment approach where two distinct therapeutic agents work together. The isoindolin-1-one derivative and SGI-110 compound create a composite therapeutic system that leverages complementary mechanisms to achieve enhanced tumor specificity and reduced off-target effects on normal cells.
2Productivity
If existing hypomethylating agents are used to treat cancer, then abnormal cell growth is inhibited, but immune recognition of tumour-associated antigens is not sufficiently boosted
Solution Approach 1:
The patent merges the hypomethylating activity of SGI-110 with MDM2-p53 inhibition. This combination not only inhibits abnormal cell growth through epigenetic modulation but also enhances immune recognition of tumour-associated antigens, as hypomethylation restores expression of immunogenic genes while p53 activation promotes immunogenic cell death and antigen presentation.
3Ease of operation
If single-agent therapy is used for cancer treatment, then treatment simplicity is maintained, but treatment efficacy is limited compared to combination therapy
Solution Approach 1:
The patent demonstrates that combination therapy with isoindolin-1-one derivatives and SGI-110 achieves superior treatment efficacy compared to single agents. The synergistic interaction between the two compounds enhances tumor cell killing, improves immune recognition, and overcomes resistance mechanisms, thereby increasing productivity (treatment efficacy) while maintaining manageable complexity through a defined two-agent regimen.
Data Source
AI summary
The invention provides a combination comprising:(i) a compound of formula (Io):or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and(ii) a compound which is SGI-110or a tautomer or a solvate or a pharmaceutically acceptable salt thereof.Also provided are pharmaceutical compositions containing the combinations and medical uses of the combinations.